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SUMMARY 
Twenty patients were treated with antilymphocyte globulin (ALG) 
which was prepared from the serum of immunized horses. The ALG 
was used as an adjuvant to azathioprine and prednisone and its use 
limited to 4 months. The surviving patients are now 1 to 7 months post- 
operative. There was 1 death, the consequence of a technical accident. 
The function in the remaining 19 patients is excellent, despite reduced 
doses of azathioprine and especially prednisone. Biopsies were obtained 
in the first 8 consecutive cases from 108 to 145 days after operation. 
There was no evidence in the specimens of either Masugi-like or se- 
rum sickness nephritis. 
Since June 1966, all patients receiving renal homotransplantation at  the 
Colorado General and Denver Veterans Administration Hospitals have been 
treated with heterologous immune globulin, prepared from the serum of horses 
which had been immunized with human spleens, thymuses, and lymph nodes. 
The steps which led to the clinical use of antilymphocyte globulin (ALG) were 
based on the pioneering studies in rodents by Waksman (16), Woodruff (13), 
Gray (3)  , Monaco (8 ) ,  Jeejeebhoy (6) , and Levey and Medawar (7) and upon 
our own previously reported investigations in dogs (4,5,10). 
The postoperative follow-up of the first 20 cases in this test series is of course 
too brief to allow conclusions about the influence that treatment with ALG 
will have upon the ultimate course of these patients. Evidence has been ob- 
tained, however, that such foreign protein therapy is of at  least short term 
value, and that i t  can be given without prohibitive toxicity for a period of 
several months as will be summarized in the present report. A far more detailed 
analysis of these cases has been published elsewhere, as well as an account of 
ALG therapy in patients with late failing homografts (11). 
METHODS 
ALG administration was planned within guidelines established from animal 
studies which included the following considerations: (I) ALG when used alone 
does not prevent or even delay rejection of all canine homografts (1, 10) ; (2) 
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it can be advantageously combined with other cornlnonly used immunosup- 
pressive agents ( 7 ,  10) ; (3) its use carries an inherent risk of anaphylaxis 
and/or nephrotoxicity even though this is apparently less than with normal 
horse seruin or globulin (1, 10) ; (4) its greatest effectiveness is with adminis- 
tration before as well as after transplantation (8,  10) ; and (5) its immuno- 
suppression is not dependent upon the productioii of lymphopenia (1,7,10).  
Because of the above information, ALG was used only as an  adjuvant agent, 
in combination u ~ i t h  azathioprine and prednisone. I n  the usual case, daily in- 
jections were started 5 days before operation, continued each day for 10 to 17 
days afterwards, then every other day for 2 weeks, twice a week for 2 ~nonths  
and once a week for 1 inonth (Fig. 1 ) .  Two patients who had anaphylactic 
reactions had therapy stopped prematurely. The ALG had a leukoagglutinin 
titer of 1:4096 to 1:32, 768, and a protein concentration of 4.6 to  9.3 gn1/100 
ml. Individual intramuscular injections were 1 to 5 1nl. The weekly protein 
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FIGURE 1. Course of a patient who received ALG therapy before and after renal 
homotransplantation. The homograft was provided by a brother. There has never been 
rejection. The prednisone therapy was started after 40 days because of the increases in 
hemagglutinin and precipitin titers. Note the subsequent fall in these measures despite 
continuation of globulin injections. 
Henlagglutinin titers against sheep red blood cells and precipitin titers were 
nionitored as indices of antibody formation against the foreign protein. The 
first 8 patients had open homograft biopsies from 108 to 145 days after trans- 
plantation. 
Azathiopririe and prednisoiie were given as described in detail elsewhere 
( l l ) ,  in a schedule wliich called for the niaxirnum doses of the former drug 
which were possible without producing leukopenia, and the smallest steroid 
doscs which were compatible with stable renal function. The effcctiveness of 
therapy was judged by analyses of tlle death rate, the quality of honiograft 
excretion, and the quantities of standard in~nlunosuppressive agents necessary 
t o  retain this function. 
Morta lz ty .  The 20 patients have hecri followed for 1 to  7 months. The oper- 
ations were 5% to 7 months ago in the first 8 cases, 2 t o  4 months in the next 8, 
and 4 to 6 weeks in the last 4. Thcre has only been 1 death (Fig. 2) ,  the four- 
teenth patient in the group, from complications stemming directly from a tech- 
nical accident. 
Nineteen of the recipients were donated kidneys hy blood relatives on essen- 
tially random selection basis; parents in 5 instances, siblings in 13, and a 
iliatcrnal uncle in the other. The twentieth patient received a cadaveric homo- 
graft from a donor who was shown by the teams of van Rood, Amos, and Tera- 
saki, wlio were working in Denver a t  the tinic, to  have a higli degree of antigen 
incompatibility with the recipient. Because of the preponderance of related 
cases, the mortality was coiriparccl to that  with 3 sequential past series of con- 
sanguineous tra~~splantatioris a t our iristitutions (Fig. 2 ) .  The early mortality 
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FIGURE 2. Mortality in paticnts treated with adjuvant ALG compared to that in 3 
preceding series of consanguineous transplantations carried out in Denver. 
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GROUP I - 23 PATIENTS (23/32)  
GROUP 2 - I I PATIENTS ( 1 1  / 14) 
GROUP 3 - 22 PATIENTS (22/25) 
GROUP 4 - 8 PATIENTS (8 /8 )  
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FIGURE 3. Week by week creatinine clearances and average daily prednisone doses 
dur~ng  the f i r ~ t  22 weeks for 8 consecutive ALG treated patients, compared to the 
same information in 3 preTiously treated series of transplantations betwen blood rela- 
tives; in these retrosp~ctive control cases, patients n-110 died before 22 weeks were cx- 
cludcd. See text for discussion. 
in the globulin-treated series was the lowest, a finding which has become mean- 
ingful a t  least in the first 12 cases since the dangerous first 3 postoperative 
months have already passed. 
P~ozction. The 19 surviving patients all have good rcnal function. A weck by 
week vicw of the average creatinine clearance of the first 8 consecutive cases 
for the first 5 months is shown in Figure 3. Function for the first 2 months was 
adequate, but after this, the cleararlces further improved. At the time of their 
biopsies from 108 to 145 days post-transplantation the various measures of 
rcnal function%were blood urea nitrogen 26.7 * 5.5 (S.D.) mg/100 ml, plasma 
creatiiliile 0.92 2 0.2 (S.D.) mg/100 ml, creatinine clearance 97.4 * 21 (S.D.) 
ml/min, inulin clearance 61 * 12.6 (S.D.) ml/min and PAH clearance 349 + 
66 (S.D.) ml/min. The filtration fraction was 17.9% * 3.3% (S.D.). Urine 
protein concentration was 5.4 * 3.6 (S.D.) mg/100 ml. 
The clearances were performed by Dr. David A. Ogden who also studied all 8 donors 
a t  the same time. The average function in the donors was not significantly different 
from that in the recipients. 
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For comparison, the average creatinine clearances are shown (Fig. 3) for 
those patients who lived for a t  least 5 months in each of the 3  preceding series 
of consanguineous transplantations; the elimination of early dcaths in the ret- 
rospective control series created a bias since only data from the best cases were 
retained. Nevcrthcless, the mean clearances from the third nionth onward were 
greater in the globulin treated group. 
Immunosuppression. The quantities of azathioprine per kg were less than 
in any of the previously treated series (11). However, the most striking de- 
clines were in the steroid doses, which were approximately half of those in the 
3  previous groups of patients who were selected as controls by virtue of their 
ability to survivc for a t  least 5 months (Fig. 3 ) .  These data,  together with 
those from the preceding section, suggest that  the reduction in the stringency 
of therapy with standard immunosuppressive drugs was not paid for by an  
increased injury to the homograft. 
Ejfect of lymphocytes. There was no statistically significant difference in the 
degree of postoperative lyinphopenia in the globulin-treated as opposed to the 
3 retrospective control series. 
Toxicity. Pain and tenderness a t  the injection sites and fever were observed 
in virtually every case. Four of the 20 patients have had anaphylactic re- 
actions whicli lasted for only a few minutes; in 2 of these cases, injections were 
continued for an additional month or longer. Increases in precipitin titers and 
antishcep red cell titers eventually occurred in every patient, but tended to  
regress either spontaneously or with the addition of steroids. 
The homograft biopsies from the first 8 cases are fully described elsewhere 
(11). None were completely normal, but there was evidence of permanent 
damage in only one case where narrowing of several interlobular arteries was 
found. 
A portion of each of the biopsies was examined by Drs. Beatrice C. Seegal 
and Konrad C. Hsu of Columbia University, New York, and by Dr. Giuseppe 
A. Andres of the University of Rome, Italy, using fluorescein-labeled and fer- 
]-itin-conjugated antihorse protein antibodies to detect the presence or absence 
of equine protein in these kidneys. None was found. 
DISCUSSION 
Experience with these cases has been distinctly encouraging in 2 respects. 
First, the early course after human renal hon~otransplantation seems to  have 
been improved by the addition of ALG to the therapeutic protocol. There has 
only been 1 death in the 20 cases, and tha t  fatality followed a serious technical 
accident. Renal function has been as good as in any comparable group of pa- 
tients previously treated in Denver, and in the cases with the longest follow-up 
i t  is distinctly better. These results have been obtained with smaller quantities 
of standard immunosuppressive agents, particularly of prednisone. 
Secondly, the use of ALG has been possible without prohibitive morbidity. 
Anaphylactic reactions were seen in 20% of the patients but these were rela- 
tively minor, and in 2 of the 4 cases a number of subsequent injections were 
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given. Two other fearcd iminunologic reactions, each with a distinctive immu- 
nologic mechanism, would have been detectable in the homograft biopsies 
since both cause intrarenal deposits of heterologous protein which can be iden- 
tified for many months afterwards with specific labeled-antibody techniques 
(2 ,  9). However, there was no evidence either that the ALG antibodies had 
reacted directly with the renal tissue (Masugi nephritis) or that these kidneys 
were the passive receptacles of soluble antigen-antibody complexes (serum 
sickness nephritis). 
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